Amgen’s Xgeva Gains FDA Nod For Use In Rare Bone Tumor

Approval of denosumab for giant cell tumor of the bone comes more than a year after Amgen’s failed bid to add a more commercially significant indication for prevention of bone metastases in patients with castrate-resistant prostate cancer.